Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma
Authors
Keywords
-
Journal
OncoImmunology
Volume 5, Issue 12, Pages e1250051
Publisher
Informa UK Limited
Online
2016-11-23
DOI
10.1080/2162402x.2016.1250051
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Chimeric Antigen Receptor (CAR) therapy for multiple myeloma
- (2016) Djordje Atanackovic et al. BRITISH JOURNAL OF HAEMATOLOGY
- Expanded and armed natural killer cells for cancer treatment
- (2016) Noriko Shimasaki et al. CYTOTHERAPY
- Dependent Coverage under the ACA and Medicaid Coverage for Childbirth
- (2016) Yaa Akosa Antwi et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase I/II trial of interleukin-15–stimulated natural killer cell infusion after haplo-identical stem cell transplantation for pediatric refractory solid tumors
- (2015) Antonio Pérez-Martínez et al. CYTOTHERAPY
- Ex Vivo–expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients
- (2015) Susann Szmania et al. JOURNAL OF IMMUNOTHERAPY
- NK Cell-based Immunotherapies in Pediatric Oncology
- (2015) Kimberly A. McDowell et al. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
- Interleukin-10 Induces Both Plasma Cell Proliferation and Angiogenesis in Multiple Myeloma
- (2015) Michael G. Alexandrakis et al. PATHOLOGY & ONCOLOGY RESEARCH
- Tissue residency of innate lymphoid cells in lymphoid and nonlymphoid organs
- (2015) G. Gasteiger et al. SCIENCE
- Immune impairments in multiple myeloma bone marrow mesenchymal stromal cells
- (2014) Thibaud André et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model
- (2012) B. E. Swift et al. HAEMATOLOGICA
- Highly activated and expanded natural killer cells for multiple myeloma immunotherapy
- (2012) T. K. Garg et al. HAEMATOLOGICA
- Bortezomib Treatment to Potentiate the Anti-tumor Immunity of Ex-vivo Expanded Adoptively Infused Autologous Natural Killer Cells
- (2012) Andreas Lundqvist et al. Journal of Cancer
- Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers
- (2010) Lei Wu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells
- (2009) A. Lundqvist et al. BLOOD
- Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy
- (2009) H. Fujisaki et al. CANCER RESEARCH
- Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma
- (2009) M A Dimopoulos et al. LEUKEMIA
- Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation
- (2008) Jumei Shi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Immunomodulatory drugs Revlimid® (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation
- (2008) Dan Zhu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells
- (2008) L. Wu et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More